Literature DB >> 32427623

Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.

Yin P Hung1, Julio A Diaz-Perez2, Gregory M Cote3, Johan Wejde4, Joseph H Schwab5, Valentina Nardi1, Ivan A Chebib1, Vikram Deshpande1, Martin K Selig1, Miriam A Bredella6, Andrew E Rosenberg2, G Petur Nielsen1.   

Abstract

Dedifferentiated chordoma is a rare chordoma subtype characterized by a high-grade sarcoma juxtaposed to conventional chordoma. We identified a series of dedifferentiated chordomas, reviewed clinicopathologic features, performed next-generation sequencing in select cases, and analyzed all related English-language publications. Our series included 7 men and 3 women (age 15 to 80 y [median: 54 y]; <1% of >1000 chordomas surveyed). The tumor (2.8 to 24.5 cm [median: 5.8 cm] in size) presented de novo or as recurrence (including postradiotherapy) in sacrum (n=5), skull base (n=2), lumbar spine (n=1), thoracic/mediastinum (n=1), and lung (n=1; as metastasis). Histologically, the dedifferentiated component (3% to 95% [median: 60%]) was pleomorphic-to-fibrosarcomatous, juxtaposed to conventional (n=8) or chondroid (n=2) component. By immunohistochemistry, the conventional/chondroid component consistently expressed cytokeratin and brachyury, whereas the dedifferentiated component showed loss of both. We identified a sacral conventional chordoma with INI1 loss, with one of the lung metastases showing biphasic histology with loss of cytokeratin and brachyury in the dedifferentiated component. Sequencing identified tumor suppressor mutations in 4 tumors, including TP53 mutations in the dedifferentiated component in 3 tumors. Of 7 patients with follow-up, 6 developed metastases; 4 died at 15 to 99 months (median: 24 mo) after dedifferentiated chordoma diagnosis. Collectively, of 87 dedifferentiated chordoma patients described in 1913-2020 (including 10 herein), the median overall survival was 20 months. In summary, dedifferentiated chordoma involves diverse sites and presents de novo, postradiotherapy, or as recurrence/metastasis months-to-years after initial diagnosis. The dedifferentiated component shows loss of brachyury and cytokeratin staining and harbors recurrent TP53 mutations, implicating tumor suppressor dysregulation in chordoma dedifferentiation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32427623     DOI: 10.1097/PAS.0000000000001501

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation.

Authors:  Mark D Murphey; Matthew J Minn; Alejandro Luiña Contreras; Kelly K Koeller; Robert Y Shih; Carrie Y Inwards; Takehiko Yamaguchi
Journal:  Skeletal Radiol       Date:  2022-09-05       Impact factor: 2.128

2.  Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.

Authors:  Wanru Duan; Boyan Zhang; Xinqiang Li; Wei Chen; Shanhang Jia; Zong Xin; Qiang Jian; Fengzeng Jian; Dean Chou; Zan Chen
Journal:  Cancer Immunol Immunother       Date:  2022-01-27       Impact factor: 6.630

3.  Clinicopathological and Prognostic Characteristics in Dedifferentiated/Poorly Differentiated Chordomas: A Pooled Analysis of Individual Patient Data From 58 Studies and Comparison With Conventional Chordomas.

Authors:  Fu-Sheng Liu; Bo-Wen Zheng; Tao-Lan Zhang; Jing Li; Guo-Hua Lv; Yi-Guo Yan; Wei Huang; Ming-Xiang Zou
Journal:  Front Oncol       Date:  2021-08-13       Impact factor: 6.244

4.  Personalized chordoma organoids for drug discovery studies.

Authors:  Ahmad Al Shihabi; Ardalan Davarifar; Huyen Thi Lam Nguyen; Nasrin Tavanaie; Scott D Nelson; Jane Yanagawa; Noah Federman; Nicholas Bernthal; Francis Hornicek; Alice Soragni
Journal:  Sci Adv       Date:  2022-02-16       Impact factor: 14.136

5.  Pediatric chordoma associated with tuberous sclerosis complex: A rare case report with a thorough analysis of potential therapeutic molecular targets.

Authors:  Kirill Anoshkin; Denis Zosen; Kristina Karandasheva; Maxim Untesco; Ilya Volodin; Ekaterina Alekseeva; Anna Parfenenkova; Eugenia Snegova; Aleksandr Kim; Marina Dorofeeva; Sergei Kutsev; Vladimir Strelnikov
Journal:  Heliyon       Date:  2022-08-19

6.  Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report.

Authors:  Christian Curcio; Robert Cimera; Ruth Aryeequaye; Mamta Rao; Nicola Fabbri; Yanming Zhang; Meera Hameed
Journal:  Genes Chromosomes Cancer       Date:  2020-10-07       Impact factor: 5.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.